Sonoma Pharmaceuticals, Inc.(SNOA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $19.5M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
SNOA Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Sonoma Pharmaceuticals, Inc. (SNOA), a Healthcare sector company. SNOA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $19.5m in revenue. Based on the latest XBRL financial filings (Q4 2026), Sonoma Pharmaceuticals, Inc. reports quarterly revenue of $5.6M, net income of $-581.0K, free cash flow of $-548.0K. Top institutional holders of SNOA by reported 13-F value include GEODE CAPITAL MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT, DRW Securities,, based on the most recent SEC filings. SNOA trades on the Nasdaq exchange and files with the SEC under CIK 1367083. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SNOA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sonoma Pharmaceuticals, Inc. directly from SEC EDGAR.
Revenue
Q4 2026
$5.6M
Net Income
Q4 2026
$-581.0K
Free Cash Flow
Q4 2026
$-548.0K
D/E Ratio
Q4 2026
0.07
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+36.7% YoYNet Income
+8.2% YoYOperating Income
+33.7% YoYEPS (Diluted)
+32.3% YoYTotal Assets
+1.9% YoYTotal Debt
+0.9% YoYOp. Cash Flow
-4369.3% YoY| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $19.5M +36.7% | $14.3M +12.2% | $12.7M -4.0% | $13.3M +5.1% | $12.6M -32.2% | $18.6M |
| Net Income | $-3.2M +8.2% | $-3.5M +28.5% | $-4.8M +6.1% | $-5.2M -1.3% | $-5.1M -28.8% | $-4.0M |
| Operating Income | $-2.5M +33.7% | $-3.7M +21.1% | $-4.7M -2.9% | $-4.6M +22.4% | $-5.9M -70.7% | $-3.4M |
| EPS (Diluted) | $-1.89 +32.3% | $-2.79 +73.8% | $-10.63 -599.3% | $-1.52 +20.8% | $-1.92 | — |
| Total Assets | $14.0M +1.9% | $13.7M -7.1% | $14.7M -9.2% | $16.2M -13.9% | $18.8M +25.7% | $15.0M |
| Total Debt | $222.0K +0.9% | $220.0K -31.9% | $323.0K -25.1% | $431.0K | $0.00 -100.0% | $1.9M |
| Operating Cash Flow | $-3.9M -4369.3% | $-88.0K +96.3% | $-2.4M +61.0% | $-6.2M -44.8% | $-4.2M -25.8% | $-3.4M |
Get alerted when SNOA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Sonoma Pharmaceuticals, Inc. including:
Top Institutional Holders of SNOA
GEODE CAPITAL MANAGEMENT, LLC
$42.5K19,941 shVANGUARD CAPITAL MANAGEMENT LLC
$40.0K18,787 shDRW Securities, LLC
$25.6K12,015 shMcKinley Carter Wealth Services, Inc.
$23.8K11,193 shMORGAN STANLEY
$4.3K2,004 shCITIGROUP INC
$3.0K1,425 shTower Research Capital LLC (TRC)
$2.6K1,231 shOSAIC HOLDINGS, INC.
$1.1K500 shBlackRock, Inc.
$241.00113 shVANGUARD FIDUCIARY TRUST CO
$213.00100 sh
| Fund | Value | Shares |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | $42.5K | 19,941 |
| VANGUARD CAPITAL MANAGEMENT LLC | $40.0K | 18,787 |
| DRW Securities, LLC | $25.6K | 12,015 |
| McKinley Carter Wealth Services, Inc. | $23.8K | 11,193 |
| MORGAN STANLEY | $4.3K | 2,004 |
| CITIGROUP INC | $3.0K | 1,425 |
| Tower Research Capital LLC (TRC) | $2.6K | 1,231 |
| OSAIC HOLDINGS, INC. | $1.1K | 500 |
| BlackRock, Inc. | $241.00 | 113 |
| VANGUARD FIDUCIARY TRUST CO | $213.00 | 100 |
More Healthcare Companies
View all Healthcare →Put SNOA on your watchlist
Track score changes the day Sonoma Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SNOA a good stock to buy?
13F Pro's AI-powered analysis of Sonoma Pharmaceuticals, Inc. (SNOA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SNOA are available on the SNOA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own SNOA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SNOA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Sonoma Pharmaceuticals, Inc.'s investment landscape.